Cardiovascular risk factors and testing of relatives amongst patients with familial hyperlipidaemia one decade after a clinical trial

Autor: S Tonstad, I Hjermann
Rok vydání: 2000
Předmět:
Zdroj: Journal of Internal Medicine. 248:111-118
ISSN: 1365-2796
0954-6820
DOI: 10.1046/j.1365-2796.2000.00692.x
Popis: Tonstad S, Hjermann I (Ulleval Hospital, Oslo, Norway). Cardiovascular risk factors and testing of relatives amongst patients with familial hyperlipidaemia one decade after a clinical trial. J Intern Med 2000; 248: 111–118. Objectives. We examined the cardiovascular disease risk factor status of men and women with familial hyperlipidaemia (FH) 10–11 years after a clinical trial and asked whether first-degree relatives had undergone lipid testing. Design setting and subjects. Subjects started lipid-lowering drugs in 1987–88. Of 60 subjects, 12 had died, one emigrated and 35 men and 12 women took part in a follow-up clinical examination in 1998. Results. Total cholesterol level was reduced by 41% and high-density lipoprotein (HDL) cholesterol level increased by 13% compared with baseline (diet alone). Low-density lipoprotein (LDL) cholesterol level was lower at the end of the trial than at follow-up (3.6 ± 1.5 vs. 4.6 ± 2.2 mmol L–1; P = 0.01) and was higher in the group taking a low dose of a statin alone compared with other drug groups. Thus, two-thirds of the subjects required adjustment of lipid-lowering drugs to reach target lipid levels. One-fifth consumed at least two food groups rich in saturated fat regularly. Body mass index (BMI) increased from 25.6 ± 2.9 to 26.8 ± 3.3 kg m–2 (P
Databáze: OpenAIRE
Externí odkaz: